Current Report Filing (8-k)
April 16 2019 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
April 12, 2019
|
ORAMED PHARMACEUTICALS INC.
|
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
001-35813
|
98-0376008
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
142
W. 57
th
Street, New York, New York
|
10018
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
844-967-2633
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.02. Termination of a Material Definitive Agreement.
On April 12, 2019, Oramed Pharmaceuticals
Inc. (the “Company”), David M. Slager, a member of the board of directors of the Company, and Regals Capital LP (“Regals”),
entered into a letter agreement terminating the letter agreement among them dated February 5, 2013 (the “2013 Letter Agreement”),
pursuant to which the Company had agreed not to (1) grant stock options with an exercise price of less than $6.00 per share or
(2) grant stock options exercisable into more than 125,000 shares of common stock of the Company without the consent of the three
largest non-founding shareholders.
As consideration for the termination of the
2013 Letter Agreement, the board of directors of the Company granted to Mr. Slager options to purchase an aggregate of 20,000
shares of common stock of the Company at an exercise price equivalent to the closing price of the Company's common stock on the
date of grant. The options will vest immediately.
1
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
By:
|
/s/ Nadav Kidron
|
|
Name:
Title:
|
Nadav Kidron
President and CEO
|
April
16, 2019
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024